Lucid Diagnostics

Lucid Diagnostics EPS

The Earnings per Share (EPS) of Lucid Diagnostics (LUCD) as of Nov 3, 2026 is -0.57 USD. In the previous year, Earnings per Share (EPS) was -0.79 USD — a change of -27.88% (higher).

EPS

-0.57USD

YoY

-27.88%

Last updated:

Earnings per Share (EPS) of Lucid Diagnostics is 2025 -0.57 USD. Earnings per Share (EPS) of Lucid Diagnostics was 2024 -0.79 USD. It decreases by -27.88% higher compared to the previous year.

The Lucid Diagnostics EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2023
-1.26 USD
Jan 1, 2024
-0.79 USD
Jan 1, 2025
-0.57 USD
Jan 1, 2026 (e)
-0.27 USD
Jan 1, 2027 (e)
-0.19 USD
Jan 1, 2028 (e)
-0.16 USD
Jan 1, 2029 (e)
-0.09 USD
Jan 1, 2030 (e)
-0.07 USD
The Lucid Diagnostics EPS history
YEAREPSYoY
est-0.07USD-22.22%
est-0.09USD-43.75%
est-0.16USD-13.51%
est-0.19USD-31.48%
est-0.27USD-52.55%
-0.57USD-27.88%
-0.79USD-37.44%
-1.26USD-16.16%
-1.50USD+87.08%
-0.80USD+259.27%
-0.22USD+87.30%
-0.12USD+292.59%
-0.03USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lucid Diagnostics Stock analysis

What does Lucid Diagnostics do? Lucid Diagnostics, Inc. generates revenue through its commercial-stage medical diagnostics technology focused on patients with gastroesophageal reflux disease (GERD). The company markets EsoGuard, a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells, and EsoCheck, a noninvasive swallowable balloon capsule catheter device used to sample these cells in office procedures. These products address the progression from chronic heartburn to esophageal precancer and lethal esophageal adenocarcinoma (EAC). The EsoCheck device consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter, featuring a soft silicone balloon with textured ridges that swab surface esophageal cells. This sampling capability enables the subsequent application of the EsoGuard assay. The company also develops EsoCure, an esophageal ablation device intended to treat dysplastic BE before it progresses to EAC, thereby expanding its therapeutic offerings within the segment of patients suffering from reflux-related conditions. Lucid Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lucid Diagnostics stock

Earnings per Share (EPS) of Lucid Diagnostics is -0.57 USD in 2025.

Earnings per Share (EPS) of Lucid Diagnostics changed from -0.79 USD to -0.57 USD, representing a -27.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Lucid Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Lucid Diagnostics

All Key Metrics — Lucid Diagnostics